Home  About us  Contact
 

New Tricks (new + trick)

Distribution by Scientific Domains
Medical Sciences75%

Kinds of New Tricks

  • dog new trick
    		•
  • old dog new trick
    		•

    Selected Abstracts

    Adjunctive Therapy for Migraine Headaches: Can We Teach an Old Dog a New Trick?

    ACADEMIC EMERGENCY MEDICINE, Issue 12 2008
    Michael T. Fitch MD
    No abstract is available for this article. [source]

    New tricks of an old molecule: lifespan regulation by p53

    AGING CELL, Issue 5 2006
    Johannes H. Bauer
    Summary As guardian of the genome the tumor suppressor p53 controls a crucial point in protection from cellular damage and response to stressors. Activation of p53 can have beneficial (DNA repair) or detrimental (apoptosis) consequences for individual cells. In either case activation of p53 is thought to safeguard the organism at large from the deleterious effects of various stresses. Recent data suggest that the function of p53 might also play a role in the regulation of organismal lifespan. Increased p53 activity leads to lifespan shortening in mice, while apparent reduction of p53 activity in flies leads to lifespan extension. Although the mechanism by which p53 regulates lifespan remains to be determined, these findings highlight the possibility that careful manipulation of p53 activity during adult life may result in beneficial effects on healthy lifespan. [source]

    RD Lawrence Lecture 2009 Old genes, new tricks: learning about blood glucose regulation from naturally occurring genetic variation in humans

    DIABETIC MEDICINE, Issue 11 2009
    A. L. Gloyn
    Abstract The study of rare monogenic forms of diabetes and pancreatic B-cell dysfunction provides an unrivalled opportunity to link a specific change in gene function with precise cellular consequences and clinical phenotype in humans. Over the past 20 years there has been considerable success in determining the genetic aetiology of a number of rare monogenic forms of diabetes, which has had a significant impact on both our understanding of normal physiology and on translational medicine. The impact of these discoveries has been substantial, with insights into both developmental biology and normal physiology. There are clear examples where determining the genetic aetiology for individuals with rare monogenic subtypes of diabetes has led to improved treatment. Although formerly in the shadow of the monogenic diabetes field, over the past 3 years there has been staggering progress in our understanding of the genetic basis of Type 2 diabetes. This has been largely as a result of genome-wide association studies and has seen the list of ,diabetes susceptibility genes' increase from three to close to 20. There is now encouraging evidence to support a potential role for genetics in determining the response of individuals with Type 2 diabetes to different therapeutic options. One of the challenges that lies ahead is determining how the non-coding genetic variants exert their pathogenicity. It is possible that parallels can be drawn from functional work on rare regulatory mutations causing monogenic forms of diabetes. However, it is more likely that comprehensive approaches will be necessary. [source]

    Gene therapy for hepatocellular carcinoma,teaching old dogs new tricks

    HEPATOLOGY, Issue 1 2001
    Simon C. Afford Ph.D.
    No abstract is available for this article. [source]

    Vitamin K to reverse the anticoagulant effect of vitamin K antagonists: can you teach an old dog new tricks?

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 3 2010
    J. D. DOUKETIS
    To cite this article: Douketis JD, Spyropoulos AC. Vitamin K to reverse the anticoagulant effect of vitamin K antagonists: can you teach an old dog new tricks? J Thromb Haemost 2010; 8: 496,8. See also Steib A, Barre J, Mertes M, Morel MH, Nathan N, Ozier Y, Treger M, Samama CM. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists? This issue, pp 499,503. [source]

    Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists?

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Issue 3 2010
    A. STEIB
    See also Douketis JD, Spyropoulos AC. Vitamin K to reverse the anticoagulant effect of vitamin K antagonists: can you teach an old dog new tricks? This issue, pp 496,8. Summary.,Background: After a vitamin K antagonist (VKA) overdose, 1,2 mg of oral vitamin K can lower the International Normalized Ratio (INR) to the therapeutic range. Objective: To establish whether oral vitamin K can substitute for heparin bridging and decrease the INR to , 1.5 before elective surgery. Methods: Patients on long-term VKAs were randomized either to heparin bridging after the last VKA dose on day , 5 before surgery (group H) or to VKA treatment until day , 2, followed by 1 mg of oral vitamin K on the day before surgery (group K). Blood clotting variables were assessed on days ,5/,2, 1 and 0, and postoperatively. If the target INR was not achieved 2 h before incision, surgery was deferred or performed after injection of prothrombin complex concentrate (PCC). Results: In 30 of 94 included patients, baseline INR was outside the chosen range (18, INR < 2; 12, INR > 3.5), leaving 34 eligible patients in group H and 30 in group K. The groups were balanced in terms of body mass index, VKA treatment duration and indication, scheduled surgery, preoperative and postoperative hemoglobin, and blood loss. The INR was significantly higher in group K on days , 1 and 0 than in group H. An INR , 1.5 was not achieved in 20 group K patients (66%). Surgery was postponed or performed after PCC injection in 12 of these 20 patients. Conclusions: Oral vitamin K (1 mg) cannot substitute for heparin bridging before surgery. In addition, one-third of patients on VKAs were exposed to a risk of bleeding (overdose) or thrombosis (underdose), thus highlighting the need for new oral anticoagulants. [source]

    Structural materials underpinning functional materials: teaching old dogs new tricks

    POLYMER INTERNATIONAL, Issue 5 2008
    William A MacDonald
    Abstract ,Structural' polymers are finding new applications underpinning new technology developments based on functional polymers. This paper discusses the use of polyester films as base substrates for flexible electronic applications based on conjugated polymers and low-temperature hydrogenated amorphous silica processing, and discusses the challenges involved in successfully developing substrates ,fit for purpose'. Copyright © 2008 Society of Chemical Industry [source]